Igc Pharma Inc (IGC)

$0.30 +0.01 (2.07%)
Market Cap 27.59M
Revenue (ttm) 1.27M
Net Income (ttm) -7.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -560.63%
Debt to Equity Ratio 0.02
Volume 427,000
Avg Vol 665,586
Day's Range N/A - N/A
Shares Out 95.04M
Stochastic %K 32%
Beta 0.32
Analysts Sell
Price Target $3.88

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 983 0998
Address:
10224 Falls Road, Potomac, United States
UCIdidmyDD
UCIdidmyDD Jan. 14 at 8:35 PM
$IGC $VFF some day…prolly sooner than later…. strategic bids loom imo
0 · Reply
Clkrrb
Clkrrb Jan. 13 at 5:39 PM
$IGC All shareholders should get some CALMA weekly from IGC to cope with no positive price movement.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:19 PM
$IGC 09:04 on Jan. 12 2026 IGC Pharma Adds Dominion Medical Associates Clinical Research Site With Lightship's Site Network #tradeideas
0 · Reply
hardrock2112
hardrock2112 Jan. 12 at 2:05 PM
$IGC
0 · Reply
Amraa2
Amraa2 Jan. 8 at 4:24 PM
$IGC if ...if only we can go to.0.5 🚶‍♂️ 😌 🤧 🤪
0 · Reply
dwiz5
dwiz5 Jan. 7 at 11:28 PM
$IGC 40K shares now tic toc g/l
1 · Reply
CharlieD85
CharlieD85 Jan. 7 at 3:07 PM
$IGC is a good one to look at this year?
1 · Reply
Amraa2
Amraa2 Jan. 7 at 2:57 PM
$IGC lets go to 0.5 and
0 · Reply
Amraa2
Amraa2 Jan. 5 at 11:26 PM
$IGC this thing is zigzagging here.Is there some news that we don't know about anybody???
1 · Reply
Amraa2
Amraa2 Jan. 5 at 11:05 PM
$IGC
0 · Reply
Latest News on IGC
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 12, 2026, 9:00 AM EST - 4 days ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 6, 2026, 8:00 AM EST - 10 days ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Jan 5, 2026, 9:00 AM EST - 11 days ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 19, 2025, 9:00 AM EST - 4 weeks ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 15, 2025, 9:00 AM EST - 4 weeks ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 10, 2025, 9:00 AM EST - 5 weeks ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 9, 2025, 9:00 AM EST - 5 weeks ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Dec 2, 2025, 9:00 AM EST - 6 weeks ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 25, 2025, 9:00 AM EST - 7 weeks ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 8:30 AM EST - 2 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 13, 2025, 9:00 AM EST - 2 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 10, 2025, 9:00 AM EST - 2 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Nov 3, 2025, 8:52 AM EST - 2 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 22, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 14, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 10, 2025, 7:50 PM EDT - 3 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Oct 7, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 29, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 24, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 22, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 9, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Sep 2, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 28, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 27, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 25, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 12, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Aug 5, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 23, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 21, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jul 10, 2025, 3:10 PM EDT - 6 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 30, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 27, 2025, 8:30 AM EDT - 7 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

Jun 23, 2025, 8:30 AM EDT - 7 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 22, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 24, 2025, 9:30 AM EDT - 9 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 21, 2025, 9:30 AM EDT - 9 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 8, 2025, 9:30 AM EDT - 10 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Apr 1, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 26, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 20, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 17, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 12, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 10, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Mar 4, 2025, 9:00 AM EST - 11 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 20, 2025, 9:00 AM EST - 11 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 18, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Feb 11, 2025, 8:30 AM EST - 1 year ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 28, 2025, 8:30 AM EST - 1 year ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

UCIdidmyDD
UCIdidmyDD Jan. 14 at 8:35 PM
$IGC $VFF some day…prolly sooner than later…. strategic bids loom imo
0 · Reply
Clkrrb
Clkrrb Jan. 13 at 5:39 PM
$IGC All shareholders should get some CALMA weekly from IGC to cope with no positive price movement.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 2:19 PM
$IGC 09:04 on Jan. 12 2026 IGC Pharma Adds Dominion Medical Associates Clinical Research Site With Lightship's Site Network #tradeideas
0 · Reply
hardrock2112
hardrock2112 Jan. 12 at 2:05 PM
$IGC
0 · Reply
Amraa2
Amraa2 Jan. 8 at 4:24 PM
$IGC if ...if only we can go to.0.5 🚶‍♂️ 😌 🤧 🤪
0 · Reply
dwiz5
dwiz5 Jan. 7 at 11:28 PM
$IGC 40K shares now tic toc g/l
1 · Reply
CharlieD85
CharlieD85 Jan. 7 at 3:07 PM
$IGC is a good one to look at this year?
1 · Reply
Amraa2
Amraa2 Jan. 7 at 2:57 PM
$IGC lets go to 0.5 and
0 · Reply
Amraa2
Amraa2 Jan. 5 at 11:26 PM
$IGC this thing is zigzagging here.Is there some news that we don't know about anybody???
1 · Reply
Amraa2
Amraa2 Jan. 5 at 11:05 PM
$IGC
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 9:48 PM
$IGC watching closes, no hurry...
0 · Reply
Amraa2
Amraa2 Jan. 5 at 9:09 PM
$IGC
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 6:25 PM
$IGC offering at 0.3, not to bad https://www.rapidticker.com/news/igc-igc-pharma-raises-capital-to-a8e8d9
0 · Reply
dwiz5
dwiz5 Jan. 2 at 6:11 PM
$IGC now sit at 38K shares G/L a matter of time…
1 · Reply
Honeybear89
Honeybear89 Jan. 2 at 5:20 PM
$IGC honestly was thinking it was popping next week but looks like we bottomed out now only up till the end of January, and who knows after
0 · Reply
Amraa2
Amraa2 Jan. 2 at 3:19 PM
$IGC we live in time of bringing a twenty cents stock down to make money.What the f*** ..
0 · Reply
Buttermaker007
Buttermaker007 Jan. 1 at 2:01 PM
$IGC let’s f goooo !
0 · Reply
angel6
angel6 Jan. 1 at 3:41 AM
$IGC why is it declining?
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 7:31 PM
$IGC Share Price: $0.28 Contract Selected: Aug 21, 2026 $2.5 Calls Buy Zone: $0.27 – $0.33 Target Zone: $0.44 – $0.54 Potential Upside: 57% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Amraa2
Amraa2 Dec. 31 at 3:31 PM
$IGC
0 · Reply
Amraa2
Amraa2 Dec. 30 at 7:08 PM
$IGC
0 · Reply
Ottway
Ottway Dec. 30 at 4:52 PM
$IGC dilution on shareholders should be criminal $CGC
1 · Reply